Menopause can bring dryness, sensitivity, acne, and loss of firmness, requiring dermatologists to adapt skin care to patients ...

Lutikizumab (ABT-981) met its primary end point and all 8 ranked secondary end points in the phase 3 INTREPID trial ...

Preview the trial data dermatology NPs and PAs will dissect in small-group sessions on AD, psoriasis, and type 2 disease at Horizons in Advanced Practice.

At the 2026 Horizons in Advanced Practice meeting, Omar Noor, MD, discussed viewing atopic dermatitis patients as type 2 inflammatory patients, growth curve data, and recent hidradenitis suppurativa ...

During Eczema Awareness Month, clinicians have an opportunity not only to raise awareness of the chronic nature of eczema but also to consider how a rapidly expanding treatment la ...

Merck. Moderna & Merck announce 5-year data for intismeran autogene in combination with KEYTRUDA (pembrolizumab) demonstrated sustained improvement in recurrence-free survival in patients with ...

Dermatology Times will host its 3rd annual Horizons in Advanced Practice meeting on October 23, 2026, in Atlanta, Georgia.

Angela Fitch, MD, co-founder and chief medical officer of Knownwell, discussed GLP-1 access strategies and a proposed ...

Houston dermatology clinicians compared severity scoring, JAK inhibitor safety data, and psychosocial counseling strategies across 3 alopecia areata patient cases. The first case involved a ...

Angela Fitch, MD, co-founder and chief medical officer of Knownwell and past president of the Obesity Medicine Association, ...

Persistence and adherence, not efficacy claims alone, distinguish IL-23 biologics in practice. Real-world claims data reveal ...

In "How Emerging Oral Therapies Target HS Inflammation," the panel explores how JAK and BTK inhibitors interrupt inflammation ...